期刊文献+

慢性肾脏病患者高磷血症治疗进展 被引量:5

Progress in the treatment of hyperphosphatemia in patients with chronic kidney disease
原文传递
导出
摘要 慢性肾脏病(CKD)自被发现以来,其发病率一直高居不下,高磷血症作为其最常见的并发症之一,也是一直困扰临床的一大难题。血磷水平能否得到有效控制与CKD患者的预后和生存时间密切相关,因此对CKD高磷血症的综合治疗对CKD患者来说至关重要,本文将从饮食的控制、含磷药物的替换、磷结合剂的选择、透析的个体化和强化等方面简要综述高磷血症的治疗进展。 Chronic kidney disease(CKD)is one of the most urgent problems in global health since its discovery,which is characterized by high prevalence rate,multiple complications and poor long-term prognosis.And hyperphosphatemia,which has not been overcome clinically,is the most common complications of CKD.Keeping blood phosphorus concentrations within a normal range is extremely important for CKD patients,which not only effectively improves their prognosis,but also extends their lifespan.This article will briefly review the progress in the treatment of hyperphosphatemia from the aspects of dietary control,replacement of phosphorus-containing drugs,comparison of phosphorus binders,excretion of urinary phosphorus,and intensification of dialysis and traditional Chinese medicine.
作者 谢伟楠 刘智 Xie Weinan;Liu Zhi(Graduate School of Bengbu Medical College,Bengbu,Anhui 233000,China;Department of Nephrology,the First People's Hospital of Huainan,Huainan,Anhui 232007,China)
出处 《中国基层医药》 CAS 2020年第11期1405-1408,共4页 Chinese Journal of Primary Medicine and Pharmacy
基金 蚌埠医学院2018年校级自然科学基金重点项目(BYKY18174)。
关键词 肾脏病学 高磷血症 肾透析 饮食习惯 药物疗法 综述 Nephrology Hyperphosphatemia Renal Dialysis Food habits Drug therapy Review
  • 相关文献

参考文献4

二级参考文献34

  • 1高玉春,李孜,唐晓红,刁骧(审校).碳酸镧治疗维持性血液透析患者高磷血症有效性和安全性的系统评价[J].中国循证医学杂志,2006,6(10):727-732. 被引量:12
  • 2Block GA, Klassen PS, Lazarus JM, et al. Mineral metab- olism, mortality, and morbidity in maintenance hemodialysis [J}. J Am Soc Nephro, 2004, 15(8): 2208-2218.
  • 3Pasternak RC, Criqui MH, Benjamin E J, et al. Atherosclerot- ic Vascular Disease Conference: Writing Group I: epidemi- ology[J]. Circulation, 2004, 109(21): 2605-2612.
  • 4Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs [J]. Kidney Int, 2006, 70(10): 1858-1865.
  • 5Adragao T, Pires A, Lucas C, et al. A simple vascular cal- cification score predicts cardiovascular risk in haemodialysis patients[J]. Nephrol Dial Transplant, 2004, 19(6): 1480- 1488.
  • 6Adeney KL, Siscovick DS, lx JH, et al. Association of se- rum phosphate with vascular and valvular calcification in moderate CKD[J]. J Am Soc Nephrol, 2009, 20(2): 381-387.
  • 7Shantouf RS, Budoff M J, Ahmadi N, et al. Total and indi- vidual coronary artery calcium scores as independent predic-tors of mortality in hemodialysis patients[J]. Am J Nephrol, 2010, 31(5): 419-425.
  • 8KDIGO clinical practice guideline for the diagnosis, evalua- tion, prevention, and treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD)[J]. Kidney Int Supp, 2009, (113): S1-130.
  • 9Hutchison AJ. Improving phosphate-binder therapy as a way forward[J]. Nephrol Dial Transplant, 2004, 19 Suppl 1: i19- 24.
  • 10Toussaint ND, Lau KK, Polkinghorne KR, et al. Attenuation of aortic calcification with lanthanum carbonate versus cal- cium-based phosphate binders in haemodialysis: A pilot ran- domized controlled trial[J]. Nephrology (Carlton), 2011, 16(3): 290-298.

共引文献65

同被引文献54

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部